Comment from Desiree B.

AnonymousSupportIndividual
Summary: An individual with a family member affected by obesity supports the action of considering obesity in clinical pharmacology. They argue that the agency should look beyond BMI to factors like body composition and include more individuals with obesity in clinical trials to ensure safer and more effective dosing.
Thank you for the opportunity to comment on this topic. As someone who has a close family member affected by obesity, I&rsquo;ve seen firsthand how complex it is and how it can impact overall health and medical care.<br/><br/>BMI is a helpful starting point, but it doesn&rsquo;t capture the full picture. It doesn&rsquo;t account for differences in body composition, fat distribution, or metabolism, all of which can affect how medications work in the body. Using additional measures like body fat percentage, waist circumference, or other clinical markers could provide more accurate guidance.<br/><br/>It&rsquo;s also important to consider the type of drug, since some medications may behave differently depending on body fat or related health conditions like diabetes.<br/><br/>Overall, I think it&rsquo;s important to include more individuals with obesity in clinical trials and look beyond BMI so dosing recommendations are safer and more effective for real patients.

View on regulations.gov →